We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > VMS

News List

Astellas’ non-hormonal VMS therapy gets FDA approval SHEM OIRERE
June 08, 2023
U.S. Food and Drug Administration has approved Veozah, the first neurokinin 3 receptor antagonist, to treat moderate to severe vasomotor symptoms.
Chime Biologics Announced the Completion of US$190 Million Series A+ Financing to Accelerate Capacity Expansion prnasia
March 26, 2021
Chime Biologics, a China-based, world-class CDMO company, announced today that it has secured a total commitment of US$190 million investment from institutional investors, and over $100 million investment has already been closed today.
Millendo Therapeutics initiates first-in-human clinical trial of MLE-301 pharmaceutical-business-review
September 30, 2020
Millendo Therapeutics announced dosing of the first subject in a Phase 1 clinical trial evaluating the safety, pharmacokinetics and preliminary efficacy of MLE-301 ...
Breast Cancer Incidence Up With Persistent Vasomotor Symptoms drugs
January 15, 2019
Postmenopausal women with persistent vasomotor symptoms (VMS) have an increased incidence of breast cancer, according to a study published online Dec. 28 in Menopause.....